INT266934

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 1.16
Pain Relevance 0.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (EGFR) cell morphogenesis (EGFR) Golgi apparatus (EGFR)
endoplasmic reticulum (EGFR) intracellular (EGFR) enzyme binding (EGFR)
EGFR (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 2 73.28 Quite High
headache 6 5.00 Very Low Very Low Very Low
Antihistamine 4 5.00 Very Low Very Low Very Low
pruritus 4 5.00 Very Low Very Low Very Low
antagonist 3 5.00 Very Low Very Low Very Low
corticosteroid 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
Pain 1 5.00 Very Low Very Low Very Low
abdominal pain 1 5.00 Very Low Very Low Very Low
cva 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Colorectal Cancer 14 98.92 Very High Very High Very High
Breast Cancer 122 96.48 Very High Very High Very High
Cancer 88 82.72 Quite High
Acne 8 70.36 Quite High
Exanthema 25 69.96 Quite High
Hypomagnesemia 9 69.60 Quite High
Advanced Or Metastatic Breast Cancer 38 50.56 Quite High
Solid Tumor 8 46.24 Quite Low
Disease 30 5.00 Very Low Very Low Very Low
Diarrhoea 21 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
anti-EGFR therapy has moderate clinical efficacy not only on EGFR-expressing
Regulation (efficacy) of EGFR-expressing Binding (only) of
1) Confidence 0.45 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.52 Pain Relevance 0
TKD shows that it is involved in EGFR dimerization, auto- and transphosphorylation
Regulation (involved) of EGFR Binding (dimerization) of
2) Confidence 0.45 Published 2009 Journal Journal of Oncology Section Body Doc Link PMC2668926 Disease Relevance 0.16 Pain Relevance 0
Cetuximab in the management of colorectal cancer

Cetuximab, a chimeric IgG1 monoclonal antibody that targets the ligand-binding domain of the epidermal growth factor receptor (EGFR), is active in metastatic colorectal cancer (mCRC).

Regulation (targets) of EGFR Binding (binding) of associated with colorectal cancer
3) Confidence 0.27 Published 2007 Journal Biologics : Targets & Therapy Section Title Doc Link PMC2721306 Disease Relevance 0.48 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox